Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Central Nervous System Malignancies
Tumour Sub-type
Neuro-oncology cancer - Neuroblastoma
Tumour stage
Early
Combined Agent(s)
Cis retinoic acid+GMCSF+IL2
Control Arm
Cis retinoic acid
Treatment Setting
<32 years old with high-risk neuroblastoma after remission and stem cell transplatation

Primary Outcome(s)

Primary Outcome(s)
EFS
Evaluated Outcome
EFS
Form(s)
Form 1

Outcome Data

PFS Control
2 years 45%
PFS Gain
Gain 20%
OS Control
5-year survival 57%
OS Gain
Gain 17%
OS HR
0.58 (0.37-0.91)

Final Score (after adjustments)

Final curative score
A

ChT; chemotherapy; DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PE, point estimate; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.